Skip to content
Sign in
Artwork for BioCentury This Week
ScienceLife SciencesBusiness

BioCentury This Week

BioCentury

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.

For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

Play
Open in
  • 31 episodes
  • weekly
  • Avg 33 min
  • English

Episodes 31

NewestOldestLongest
All11Unplayed11In progress0Played0
Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • S7 · E371
    June 11 · 32 min

    Ep. 371 - Moving faster at the academia-industry interface

    Getting into the clinic fast to de-risk assets has become the name of the game in biotech, and at the academia-industry interface, too. From AI to NAMs to starting a Phase I trial in the U.S., BioCentury’s 3rd Grand Rounds-U.S. conference brought together academic innovators, biopharma leaders and early-stage investors to debate key bottlenecks in translation and how to make early-stage R&D investible. Sam Blackman, entrepreneur in residence at GV and co-founder of Day One Biopharmaceuticals, and Aaron Coe, managing director of innovation for the Allen Institute, joined BioCentury’s analysts on stage last week in Seattle for a podcast recording to wrap up Grand Rounds and discuss key takeaways from the event. Editor’s note: We invite you to join BioCentury and Regional Host Chairs Forbion and BGV at our next edition of BioCentury Grand Rounds, scheduled for Sept. 23-25 in Amsterdam. View full story: https://www.biocentury.com/article/659729 #TranslationalScience #DrugDevelopment #BiopharmaInnovation #AcademicInnovation #GrandRoundsUS 00:53 - World-Class Regional Hosts 02:56 - Building Grand Rounds Community 05:21 - Two Nobels, One City 07:43 - AI Goes End-to-End 09:47 - The Data Problem 14:12 - AI, Animals, Australia 19:53 - Study Startup Bottlenecks 26:11 - Early Science Investability To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    • Transcript
    • Chapters
  • S7 · E370
    June 9 · 34 min

    Ep. 370 - Calmer waters for FDA; Servier, Lilly deals

    FDA’s new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdin discusses how FDA’s new, interim leaders have changed the tone at the agency and why they are putting medicines derailed under former FDA Commissioner Marty Makary back on track. Usdin also highlights FDA’s new real-time clinical trials initiative. BioCentury’s analysts then turn to deals, including an analysis of the 20 deals Eli Lilly has done this year; Servier’s move to expand in neurology via BD; and Monday’s billion-dollar deals by Incyte, which will acquire Vega Therapeutics, and Johnson & Johnson, which is buying Firefly Bio. The team also discusses Grand Rounds U.S., held last week in Seattle, including the conference’s Rising Star prize winner Sylvain Simon of Fred Hutchinson Cancer Center. View full story: https://www.biocentury.com/article/659699 #FDA #BiopharmaDeals #ClinicalTrials #BiotechMA #GrandRoundsUS 01:23 - Grand Rounds Seattle Takeaways 04:43 - FDA's New Leaders 11:48 - FDA's Real Time Trials Pilot 20:40 - Servier Bets on Neuro 25:33 - Lilly's Deal Spree 30:21 - Dealmaking Roundup To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    • Transcript
    • Chapters
  • S7 · E369
    June 2 · 39 min

    Ep. 369 - ASCO advances, China innovation & U.S. science under threat

    Revolution Medicines continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the detailed data for the company’s daraxonrasib, Akeso’s Harmoni-6 readout, as well as other results from the meeting. BioCentury’s analysts then argue that U.S. biotech executives and policymakers should embrace the challenges and opportunities that come with the rise of innovation in China — rather than sticking their heads in the sand. They also discuss why leaders of the U.S.’s biggest drug companies should use their influence to stop an OMB proposal that threatens the foundations of U.S. science. Plus: takeaways from BioCentury's conversation with Alkermes CEO Richard Pops on The BioCentury Show. View full story: https://www.biocentury.com/article/659629 #ASCO #PancreaticCancer #BiotechInnovation #ChinaBiotech #DrugDevelopment 00:00 - Introduction 01:49 - ASCO: RevMed 06:50 - ASCO: Akeso 16:33 - China U.S. Biotech Rivalry 24:15 - Science Under Threat 36:29 - Richard Pops Takeaways To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    • Transcript
    • Chapters
  • S7 · E368
    May 27 · 33 min

    Ep. 368 - ASCO Preview, China Policy, ADC Linkers

    At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight ADCs, bispecifics and diagnostics that are broadening the field’s approach to the cancer. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss Revolution’s daraxonrasib, other readouts to watch for in pancreatic cancer and what else is on BioCentury’s radar at this year’s American Society of Clinical Oncology meeting. BioCentury’s analysts also discuss a push by China hawks in Congress to get the Trump administration to invoke national security powers to narrow Chinese life sciences companies’ access to U.S. markets, technology and capital; an initiative by Rep. Jake Auchincloss (D-Mass.) that seeks to modernize how clinical trials are conducted in the U.S.; and a BioCentury analysis on new antibody-drug conjugate linker techniques. This episode of the BioCentury podcast is brought to you by Jeito Capital. View full story: https://www.biocentury.com/article/659581 #Biopharma #ASCO2026 #PancreaticCancer #ClinicalTrials #ADCInnovation 00:01 - Sponsor Message: Jeito Capital 02:26 - ASCO Preview 14:24 - U.S. China Policy 22:48 - Modernizing U.S. trials 27:17 - Optimizing ADC Linkers To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    • Transcript
    • Chapters
  • S7 · E367
    May 19 · 30 min

    Ep. 367 - FDA, obesity targets and the rise of DACs

    Marty Makary wasn’t the only official on the outs at FDA last week in another tumultuous turn of events for the regulatory agency. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdin discusses who’s in, who’s out and what’s next at FDA — and why the changes may mean more conservative decision-making at the agency in the near term. BioCentury’s analysts also discuss the new obesity targets that came to light at last week’s annual meeting of the European Congress on Obesity, the market for biotech IPOs, and the emergence of degrader-antibody conjugates. DACs pair the tissue-targeting logic of antibody-drug conjugates (ADCs) with the catalytic activity of protein degraders. 3C Therapeutics is the latest entrant to the field, pitching its TriCore platform as a modular backbone for DAC generation. This episode of the BioCentury podcast is brought to you by Jeito Capital. View full story: https://www.biocentury.com/article/659510 #FDA #ObesityDrugDevelopment #BiotechIPO #DACs #Biopharma 00:01 - Sponsor Message: Jeito Capital 02:53 - FDA Leadership Shakeup 10:35 - Obesity Target Hunt 16:07 - Biotech IPOs 20:02 - Degrader-antibody Conjugates 28:42 - Serif: Non-viral DNA To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    • Transcript
    • Chapters
  • S7 · E366
    May 12 · 43 min

    Ep. 366 - Europe's need for speed: Bio€quity takeaways

    China’s speed in generating first-in-human data has catalyzed a race across the globe to reshape regulatory requirements to compete. BioCentury’s analysts, along with special guests Detlev Mennerich, head of Boehringer Ingelheim Venture Fund, and Mehdi Ainouche, partner at Jeito Capital, discussed where Europe fits in that landscape and other takeaways from the 26th annual Bio€quity Europe conference in Prague. This special episode of BioCentury This Week has been brought to you by Jeito Capital. View full story: https://www.biocentury.com/article/659450 #EuropeanBiotech #ClinicalDevelopment #BiopharmaInnovation #DrugDevelopment #LifeSciencesStrategy 00:01 - Sponsor Message: Jeito Capital 03:14 - China’s Speed Challenge 04:08 - Europe’s Clinical Trial Opportunity 11:48 - Speed vs. Capital Efficiency 15:52 - Takeaways from Richard Pazdur 19:58 - FDA Uncertainty and Global Alternatives 26:50 - Biopharma M&A Outlook 33:34 - The Next Wave of Science To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    • Transcript
    • Chapters
  • S7 · E365
    May 12 · 30 min

    Ep. 365 - Thin ice for Makary, redosing AAVs

    Marty Makary’s hold on the top job at FDA is slipping, with White House leaks about President Donald Trump’s displeasure with the FDA commissioner shifting the question from whether he will be fired to when. On the latest BioCentury This Week podcast, Washington Editor Steve Usdin discusses the pressures on Makary, how long he will hold onto his post, and the leading candidates to succeed him. BioCentury’s analysts then discuss solutions to AAV’s redosing problem, which could reignite industry interest in a modality that has fallen out of favor, and other topics in the spotlight at this week’s American Society of Gene and Cell Therapy annual meeting. The analysts also discuss opportunities to attend and present academic posters at the third BioCentury Grand Rounds U.S. conference June 3-5 in Seattle. This episode of the BioCentury This Week podcast has been brought to you by Jeito Capital. View full story: https://www.biocentury.com/article/659426 #FDA #GeneTherapy #AAV #CellTherapy #Biopharma 00:01 - Sponsor Message: Jeito Capital 01:43 - Bio€quity Europe Prague Highlights 04:54 - Makary on Thin Ice 14:37 - Grand Rounds Poster Pitch 16:40 - AAVs at ASGCT To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    • Transcript
    • Chapters
  • S7 · E364
    May 5 · 32 min

    Ep. 364 - UCB’s Candid buy, Grand Rounds and leukodystrophies

    UCB is the latest biopharma player to consummate a multibillion-dollar deal amid a surge in biotech M&A activity, acquiring Ken Song’s Candid Therapeutics, one of the leading T cell engager companies. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the $2 billion takeout and the opportunity in the TCE space. They also assess the drug development landscape for leukodystrophies and the market for biotech IPOs on NASDAQ, where a trio of biotechs exceeded expectations last week, lifting hopes that the window for new listings is broadening. Looking ahead to June, the analysts also preview the third BioCentury Grand Rounds U.S. conference. This episode of the BioCentury This Week podcast was brought to you by Jeito Capital. View full story: https://www.biocentury.com/article/659365 #BiotechMA #TCellEngagers #Leukodystrophy #BiotechIPO #TranslationalScience 00:01 - Sponsor Message: Jeito Capital 02:19 - Grand Rounds Seattle 12:47 - UCB’s Candid Buy 20:27 - Leukodystrophies Pipeline 27:22 - Biotech IPOs To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    • Transcript
    • Chapters
  • S7 · E653
    April 28 · 30 min

    Ep. 363 - New targets at AACR, biopharma deals, Kurma fund

    More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the focus on new ways to enhance the immune response against solid tumors and to make existing immunotherapies more effective. On the latest BioCentury This Week podcast, BioCentury’s analysts assess the new targets identified among the thousands of abstracts at AACR, as well as emerging pan-RAS inhibiting antibody-drug conjugates. The analysts also discuss Eli Lilly's latest deal — for a JAK-2 inhibitor from Ajax — and what the current pace of M&A and partnerships says about the state of biopharma dealmaking. This episode also features Kurma Partners’ new venture fund and the latest in BioCentury’s Emerging Company Profile series, spotlighting U.K.-based rheumatoid arthritis company Elevara Medicines. This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech. View full story: https://www.biocentury.com/article/659298 #AACR #OncologyTargets #Immunotherapy #BiotechMA #ADC 00:01 - Sponsor Message: IQVIA Biotech 02:50 - AACR: New Targets 11:08 - AACR: Pan-RAS Inhibitor ADCs 15:35 - Biopharma Deals 23:53 - Kurma's New Venture Fund 27:28 - Emerging Company Profile: Elevara To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    • Transcript
    • Chapters
  • S7 · E362
    April 23 · 25 min

    Ep. 362 - AACR: Data and de-risking

    Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year’s American Association for Cancer Research meeting in San Diego as biotechs unveiled their latest preclinical and first-in-human oncology data. On a special edition of the BioCentury This Week podcast, IQVIA Biotech CMO James Kyle Bryan joins BioCentury’s analysts to discuss what AACR revealed about modalities gaining traction, plus shares his perspective on de-risking clinical development and eliminating the “white space” that delays biotechs’ timelines in the clinic. This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech. View full story: https://www.biocentury.com/article/659235 #AACR #BispecificAntibodies #ADC #OncologyData #ClinicalDevelopment 00:01 - Sponsor Message: IQVIA Biotech 01:43 – AACR Early Signals 05:17 – Antibody Innovation 09:22 – Dual Payload ADCs 13:48 – De-Risking Drug Development 19:16 – Looking Ahead to ASCO To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    • Transcript
    • Chapters
  • S7 · E361
    April 21 · 44 min

    Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers

    The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDAQ-traded biotech and what could soon become the largest biotech IPO ever on NASDAQ. On the latest BioCentury This Week, BioCentury’s analysts discuss Eli Lilly's $3.25 billion takeout of in vivo CAR T company Kelonia, the market debut by obesity play Kailera and an upsized follow-on by Revolution on the back of its pancreatic cancer data. The analysts also discuss how autoimmune T cell engagers are diverging from their oncology roots and the potential implications of President Donald Trump’s executive order on psychedelic therapies. BioCentury’s analysts also take time to remember Sofinnova Partners’ Denis Lucquin, father of French biotech. This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech. View full story: https://www.biocentury.com/article/659183 #BiotechMA #BiotechIPO #CART #TCellEngagers #PsychedelicMedicine 00:01 - Sponsor Message: IQVIA Biotech 04:20 - Lilly's Kelonia Buy 10:31 - T Cell Engagers 23:07 - Psychedelics Executive Order 35:14 - CBER Director Search 37:37 - Public Markets Roundup 42:14 - Remembering Denis Lucquin To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    • Transcript
    • Chapters
Showing 21–31 of 31 episodes